Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry

INTRODUCTION: Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germany. MET...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cardiol Ther
Main Authors: Zeymer, Uwe, Lober, Christiane, Wolf, Andreas, Richard, Frank, Schäfer, Heinrich, Taggeselle, Jens, Kabitz, Hans-Joachim, Prondzinsky, Roland, Süselbeck, Tim
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7584711/
https://ncbi.nlm.nih.gov/pubmed/32638266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40119-020-00188-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki